Skip to Content
Is it time for a new insulin treatment? Learn more >>

Metformin / repaglinide Pregnancy and Breastfeeding Warnings

Metformin / repaglinide is also known as: PrandiMet

Metformin / repaglinide Pregnancy Warnings

Animal studies in rat offspring have shown nonteratogenic skeletal deformities consisting of shortening, thickening, and bending of the humerus when dams received 15 times expected clinical exposure of repaglinide on days 17 to 22 of gestation and during lactation. Teratogenicity was not observed in rats or rabbits exposed to doses of 40 times and 0.8 times expected human exposure, respectively, throughout pregnancy. Animal studies with metformin do not indicate harmful effects with respect to pregnancy, embryo or fetal development, birth or postnatal development. There are no controlled data in pregnant women with combination use or use of the individual components. In humans, abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital abnormalities. Most experts recommend insulin use during pregnancy to maintain blood glucose levels. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Use only if clearly needed US FDA pregnancy category: C

See references

Metformin / repaglinide Breastfeeding Warnings

Use is not recommended Excreted into human milk: repaglinide (Unknown); metformin (Yes) Excreted into animal milk: repaglinide (Yes); metformin (Yes) Comments: Blood glucose should be monitored in the breastfed infant.

Measurable levels of repaglinide have been detected in the breast milk of rats resulting in lowered blood glucose levels in the pups. Metformin drug levels in breastfed infants are expected to be 0.5% of their mother's weight-adjusted dosage. There is no information on combination use of these agents in breastfed infants or its excretion into human milk.

See references

References for pregnancy information

  1. "Product Information. PrandiMet (metformin-repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.

References for breastfeeding information

  1. "Product Information. PrandiMet (metformin-repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
  2. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide